December 16, 2020 -- Thermo Fisher Scientific announced it will build a new plasmid DNA manufacturing facility in Carlsbad, CA.
The current good manufacturing practice (cGMP) site will expand Thermo Fisher's clinical and commercial capabilities for plasmid DNA, a raw material that is used to develop and manufacture cell and gene-based therapies, including cancer treatments and messenger RNA (mRNA) vaccines.
Also, the 67,000-sq-ft facility will produce large-scale plasmid DNA as a primary drug substance for DNA therapies. The facility will be equipped with equipment up to 1,000-L scale, digital connectivity, and data visibility capabilities.
The expansion will complement viral vector services that the company provides from its facilities in Cambridge, MA, Lexington, MA, Plainville, MA, and Alachua, FL, as well as its cell therapy manufacturing facility in Princeton, NJ, and cryocenter in Germany.
It is expected to be completed in the first half of 2021 and will add approximately 150 new jobs in the next year.
Copyright © 2020 scienceboard.net